To learn more about my research interests and the types of projects I have worked on, please see the following list of publications that I have been a part of.


  • Case Studies in Bayesian Methods for Biopharmaceutical CMC (2022). P. Faya and T. Pourmohamad. Chapman and Hall/CRC. [link]
  • Bayesian Optimization with Application to Computer Experiments (2021). T. Pourmohamad and H.K.H Lee. Springer Cham. [link]

Book Chapters

  • Bayesian Dissolution Testing (2022). T. Pourmohamad and R. Richardson. In Case Studies in Bayesian Methods for Biopharmaceutical CMC. Chapman and Hall/CRC. 57-84. [link]

Journal Articles

  • Statistical Modeling Approaches for the Comparison of Dissolution Profiles (2023). T. Pourmohamad and H.K.T. Ng. Pharmaceutical Statistics. 22(2):248-265. [link]
  • Statistical Considerations for Design and Analysis of Stability, Comparability and Formulation Tests (2023). D. Coleman and T. Pourmohamad. Pharmaceutical Statistics. 22(2):248-265. [link]
  • Sequential Bayes Factors for Sample Size Reduction in Preclinical Experiments with Binary Outcomes (2022). T. Pourmohamad and C. Wang. Statistics in Biopharmaceutical Research. [link]
  • Gaussian Process Modeling for Dissolution Curve Comparisons (2022). T. Pourmohamad, C. M. Oliva Avilés, and R. Richardson. The Journal of the Royal Statistical Society, Series C. 71(2):331-351. [link]
  • Continuous method validation: beyond one-time studies to characterize analytical methods (2023). P. Faya, S. Novick, J.W. Seaman Jr., J.J. Peterson, T. Pourmohamad, D. Banton, and Y. Zheng. Statistics in Biopharmaceutical Research. 15(1):225-233. [link]
  • First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. (2022). T.W. Kim, H.A. Burris, M.J. de Miguel Luken, M.J. Pishvaian, Y. Bang, M. Gordon, A. Awada, D.R. Camidge, F.S. Hodi, G.A. McArthur, W.H. Miller, A. Cervantes, L.Q. Chow, A.M. Lesokhin, A. Rutten, M. Sznol, D. Rishipathak, S. Chen, E. Stefanich, T. Pourmohamad, M. Anderson, J. Kim, M. Huseni, I. Rhee, L.L Siu. Clinical Cancer Research. [link]
  • Bayesian Optimization via Barrier Functions (2022). T. Pourmohamad and H.K.H Lee. Journal of Computational and Graphical Statistics. 31(1):74-83. [link]
  • CompModels: A Suite of Computer Model Test Functions for Bayesian Optimization (2021). T. Pourmohamad. The R Journal. 13(2):441-449. [link]
  • Validating Container Closure Integrity with Statistically Based Tests (2021). D. Coleman, T.Pourmohamad, Y. Webb Vargas, and M. Mossman. PDA Journal of Pharmaceutical Science and Technology. (75)6:465-473. [link]
  • A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia (2021). N. Daver, A. Salhotra, J.M. Brandwein, N.A. Podoltsev, D.A. Pollyea, J.G. Jurcic, S. Assouline, K. Yee, M. Li, T. Pourmohamad, D. Samineni, T. Sumiyoshi, A. Vaze, R.C. Dere, C. Ma, and J. Cooper. American Journal of Hematology. (96)5:E175-E179. [link]
  • Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patient (2021). L.L. Ngai, C.Y. Ma, O. Maguire, A.D. Do, A. Robert, A.C. Logan, E.A. Griffiths, M.J. Nemeth, C. Green, T. Pourmohamad, B.J. van Kuijk, A.N. Snel, Z.W. Kwidama, B. Venniker-Punt, J. Cooper, M.G. Manz, B.T. Gjertsen, L. Smit, G.J. Ossenkoppele, J.J.W.M. Janssen, J. Cloos, and T. Sumiyoshi. European Journal of Haematology. 107(3):343-353. [link]
  • The Utility of Novel Biomarkers in Mice for Drug Development Studies (2021). A.O. Adedeji, T. Pourmohamad, Y.-Z. Gu, J. Kanerva, Y. Chen, E. Atabakhsh, M. Tackett, F. Chen, B. Bhatt, T. Gury, O. Dorchies, M. Sonee, M. Morgan, J. Burkey, J.-C. Gautier, J. McDuffie. International Journal of Toxicology. 40(1):15-25.[link]
  • The Statistical Filter Approach to Constrained Optimization (2020). T. Pourmohamad and H.K.H. Lee. Technometrics. 62(3):303-312 [link]
  • Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GCD-0919) Administered with PD-l1 Inhibitor (Atezolizumab) in Adavnced Solid Tumors (2019). K.H. Jung, P.M. LoRusso, H.A. Burris, M.S. Gordon, Y. Bang, M.D. Hellman, A. Cervantes, M. Ochoa de Olza, A. Marabelle, F.S. Hodi, M. Ahn, L.A. Emens, F. Barlesi, O. Hamid, E. Calvo, D.F. McDermott, H. Soliman, I. Rhee, R. Lin, T. Pourmohamad, J. Suchomel, A. Tsuhako, K.M. Morrissey, S. Mahrus, R. Morley, A. Pirzkall, S.L. Davis. Clinical Cancer Research. [link]
  • Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies (2019). A.O. Adedeji, T. Pourmohamad, Y. Chen, J. Burkey, C.J. Bettes, S.J. Bickerton, M. Sonee, J.E. McDuffie. International Journal of Toxicology. 38(1):12-22 [link]
  • Phase I Study of the Anti-beta5-alpha1 Monoclonal Antibody MINT1526A With or Without Bevacizumab in Patients with Advanced Solid Tumors (2018). C.D. Weekes, L.S. Rosen, A. Capasso, K.M. Wong, W. Ye, M. Anderson, B. McCall, J. Fredrickson, E. Wakshull, S. Eppler, Q. Shon-Nguyen, R. Desai, M. Huseni, P.S. Hedge, T. Pourmohamad, I. Rhee, A. Bessudo. Cancer Chemotherapy and Pharmacology. 82(2):339-351 [link]
  • Multivariate Stochastic Process Models for Correlated Responses of Mixed Type (2016). T. Pourmohamad and H.K.H. Lee. Bayesian Analysis. 11 (3):797-820 [link]
  • Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment (2012). A. Bharatha, M.E. Faughnan, H. Kim, T. Pourmohamad, C.E. McCulloch, M.T. Lawton, C. Dowd, T. Krings, W.L. Young, and K.G. Terbrugge. Stroke. 43:72-78 [link]
  • Silent Intralesional Microhemorrhage as a Risk Factor for Brain Arteriovenous Malformation Rupture (2012). Y. Guo, T. Saunders, H. Su, H. Kim, D. Akkoc, D.A. Saloner, S. Hetts, C. Hess, M.T. Lawton, A.W. Bollen, T. Pourmohamad, C.E. McCulloch, T. Tihan, W.L. Young. Stroke. 43:1240-1246 [link]
  • An Admission Bioclinical Score to Predict 1-Year Outcomes in Patients Undergoing Aneurysm Coiling (2012). V. Degos, C.C. Apfel, P. Sanchez, C. Colonne, I. Renuit, F. Clarançon, A. Nouet, A.L. Boch, T. Pourmohamad, H. Kim, P.A. Gourraud, W.L. Young, L. Puybasset. Stroke. 43:1253-1259 [link]
  • Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue (2012). M.P. Kahle, B. Lee, T. Pourmohamad, A. Cunningham, H. Su, H. Kim, Y. Chen, C.E. McCulloch, N.M. Barbaro, M.T. Lawton, W.L. Young, G.J. Bix. Neuroreport. 23(10):627-30 [link]
  • Evaluating Performance of a New Combined Grading Scale for Selecting Patients with Brain Arteriovenous Malformations for Surgery (2012). H. Kim, T. Pourmohamad, C.E. McCulloch, M.T. Lawton, and W.L. Young. Stroke. 43(9):2497-9 [link]
  • Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: Gene-phenotype correlations (2012). T. Nishida, M.E. Faughnan, T. Krings, M. Chakinala, J.R. Gossage, W.L. Young, H. Kim, T. Pourmohamad, K.J. Henderson, S.D. Schrum, M. James, N. Quinnine, A. Bharatha, K.G. Terbrugge, R.I. White Jr. American Journal of Medical Genetics. 158A(11):2829-34 [link]
  • Cerebellar Arteriovenous Malformations: Anatomical Subtypes, Surgical Results, and Increased Predictive Accuracy of the Supplementary Grading System (2012). A. Rodriguez-Hernandez, H. Kim, T. Pourmohamad, W.L. Young, and M.T. Lawton. Neurosurgery. 71(6):1111-24 [link]


  • Surrogates: Gaussian Process Modeling, Design, and Optimization for the Applied Sciences (2021). T. Pourmohamad. Technometrics. (62)3:303-312. [link]